74619-50-4

Basic information

• Product Name: bis-3,5-(2'-hydroxyphenyl)-1H-1,2,4-triazole
• Synonyms: bis-3,5-(2'-hydroxyphenyl)-1H-1,2,4-triazole
• CAS NO: 74619-50-4
• Molecular Weight: 253.26
• Mol File: 74619-50-4.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: bis-3,5-(2'-hydroxyphenyl)-1H-1,2,4-triazole(CAS DataBase Reference)
• NIST Chemistry Reference: bis-3,5-(2'-hydroxyphenyl)-1H-1,2,4-triazole(74619-50-4)
• EPA Substance Registry System: bis-3,5-(2'-hydroxyphenyl)-1H-1,2,4-triazole(74619-50-4)

Safety Data

• Hazardous Substances Data: 74619-50-4(Hazardous Substances Data)

Upstream product

• 63963-47-3 6,6'-(1,2,4-Dithiazolidin-3,5-yliden)-bis-2,4-cyclohexadien-1-on 
• 65-45-2 salicylamide 
• 69-72-7 salicylic acid 
• 53638-81-6 2,2’-(4-amino-4H-1,2,4-triazole-3,5-diyl)diphenol 
• 1218-69-5 2-(2-hydroxyphenyl)-4H-benzo[e][1,3]oxazin-4-one 
• 74619-49-1 3,5-bis(2-hydroxyphenyl)-1H-1,2,4-oxadiazole 
• 613-94-5 benzoic acid hydrazide 
• 1441-87-8 salicyloyl chloride 
• 1972-71-0 2-hydroxy-N-(2-hydroxybenzoyl)benzamide 
• 90681-68-8 <2-(2-Hydroxyphenyl)-1,3-benzoxazin-4-yliden>-4-nitrophenylacetonitril 
• 86245-83-2 2-(o-hydroxyphenyl)-4-oxo-1,3-benzoxazinium perchlorate 

Downstream Products

• 110981-88-9 Co⁽²⁺⁾*C₂HN₃(C₆H₄O)2^(2-)=Co(C₂HN₃(C₆H₄O)2) 
• 110981-86-7 Cu⁽²⁺⁾*C₂HN₃(C₆H₄O)2^(2-)=Cu(C₂HN₃(C₆H₄O)2) 
• 110981-87-8 Ni⁽²⁺⁾*C₂HN₃(C₆H₄O)2^(2-)=Ni(C₂HN₃(C₆H₄O)2) 

Relevant articles and documents

Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties

Deferasirox, ExJade, is an FDA-approved iron chelator used for the treatment of iron overload. In this work, we report several fluorescent deferasirox derivatives that display unique photophysical properties, i.e., aggregation-induced emission (AIE), excited state intramolecular proton transfer, charge transfer, and through-bond and through-space conjugation characteristics in aqueous media. Functionalization of the phenol units on the deferasirox scaffold afforded the fluorescent responsive pro-chelator ExPhos, which enabled the detection of the disease-based biomarker alkaline phosphatase (ALP). The diagnostic potential of these deferasirox derivatives was supported by bacterial biofilm studies.

Synthesis, Biological Evaluation and Molecular Docking of Deferasirox and Substituted 1,2,4-Triazole Derivatives as Novel Potent Urease Inhibitors: Proposing Repositioning Candidate

A series of new deferasirox derivatives were synthesized through the reaction of monosubstituted hydrazides with 2-(2-hydroxyphenyl)-4H-benzo[e][1,3]oxazin-4-one. For the first time, deferasirox and some of its derivatives were evaluated for their in vitro inhibitory activity against Jack bean urease. The potencies of the members of this class of compounds are higher than that of acetohydroxamic acid. Two compounds, bearing tetrazole and hydrazine derivatives (bioisoester of carboxylate group), represented the most potent urease inhibitory activity with IC50 values of 1.268 and 3.254 μm, respectively. In silico docking studies were performed to delineate possible binding modes of the compounds with the enzyme, urease. Docking analysis suggests that the synthesized compounds were anchored well in the catalytic site and extending to the entrance of binding pocket and thus restrict the mobility of the flap by interacting with its crucial amino acid residues, CME592 and His593. The overall results of urease inhibition have shown that these target compounds can be further optimized and developed as a lead skeleton for the discovery of novel urease inhibitors.

Proton transfer triggered proton transfer: A self-assisted twin excited state intramolecular proton transfer

The double excited state intramolecular proton transfer (ESIPT) of 3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazole (bis-HPTA), a molecule possessing two intramolecular hydrogen bonded donor-acceptor pairs, has been investigated. The molecule undergoes not only